U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H25NO2
Molecular Weight 311.418
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ADIPHENINE

SMILES

CCN(CC)CCOC(=O)C(C1=CC=CC=C1)C2=CC=CC=C2

InChI

InChIKey=JGOAIQNSOGZNBX-UHFFFAOYSA-N
InChI=1S/C20H25NO2/c1-3-21(4-2)15-16-23-20(22)19(17-11-7-5-8-12-17)18-13-9-6-10-14-18/h5-14,19H,3-4,15-16H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H25NO2
Molecular Weight 311.418
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Adiphenine is a ternary amino ligand. It is used as a local anesthetic that reduces the frequency of acetylcholine-induced single-channel currents. It was originally introduced as a spasmolytic agent. Adiphenine reduced the muscle tone of the gastrointestinal tract, bile duct and gallbladder, bronchi, bladder. It affects the tone of the muscles of the eye, causing the pupil dilated (mydriasis), increased intraocular pressure, and paralysis of accommodation. Influences on the cardiovascular system, causing tachycardia and improving AV-conduction. Adiphenine side effects are: nausea, vomiting, heartburn, dizziness, headache. Adiphenine has not been widely used clinically.

CNS Activity

Curator's Comment: Known to be CNS penetrant in mice and rats. Human data not available.

Approval Year

Targets

Targets

Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Trasentine

Approved Use

Adiphenine is indicated for the treatment of spasms of smooth muscles of the digestive tract, bile ducts, bronchi.
Primary
Trasentine

Approved Use

Unknown
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [Activation >10 uM]
no [Activation >10 uM]
no [Activation >10 uM]
yes [Activation 5.01187 uM]
yes [Activation 5.01187 uM]
yes [IC50 158.4 uM]
yes [Inhibition 10 uM]
yes [Inhibition 10 uM]
PubMed

PubMed

TitleDatePubMed
By the way, doctor. I've been taking Paxil for depression for about six months. Although it's helped my symptoms of depression, I've lost interest in sex. Aside from stopping the medication, is there any way to regain my sexual function?
2001 Feb
Receptor protection studies to characterize neuronal nicotinic receptors: tubocurarine prevents alkylation of adrenal nicotinic receptors.
2001 Feb 9
Paxil and self-scratching.
2001 Jan
New use for Paxil approved.
2001 Jul-Aug
Serotonin reuptake inhibitor (Paxil) does not prevent the vasovagal reaction associated with carotid sinus massage and/or lower body negative pressure in healthy volunteers.
2002 Sep 17
Concerns about Paxil for children.
2003 Sep-Oct
A taxpayer-funded clinical trials registry and results database.
2004 Dec
Antidepressant medication use among First Nations peoples residing within British Columbia.
2004 Nov 5
Acute and chronic toxicity of five selective serotonin reuptake inhibitors in Ceriodaphnia dubia.
2004 Sep
[Clinical effects of paxil in poststroke rehabilitation].
2005
Serotonin and depression: a disconnect between the advertisements and the scientific literature.
2005 Dec
Medicine as a corporate enterprise, patient welfare centered profession, or patient welfare centered professional enterprise?
2005 Nov
Paxil: part of the process.
2006 Apr
Disease mongering in drug promotion: do governments have a regulatory role?
2006 Apr
Rare case of serotonin syndrome with therapeutic doses of paroxetine.
2006 Nov-Dec
Effect of generic-only drug benefits on seniors' medication use and financial burden.
2006 Sep
The SSRI trials in children: disturbing implications for academic medicine.
2006 Spring
Patterns of prescription and self-medication for treating primary dysmenorrhea in a Mexican population.
2007
Paroxetine versus placebo and other agents for depressive disorders: a systematic review and meta-analysis.
2007 Dec
Generic entry, reformulations and promotion of SSRIs in the US.
2008
Paroxetine.
2008 Apr
Trial registration for public trust: making the case for medical devices.
2008 Jan
Nutritional therapies for mental disorders.
2008 Jan 21
[The anxyolytic effect of mild hypobaric hypoxia in a model of post-traumatic stress disorder in rats].
2008 Jul-Aug
Sequestered evidence and the distortion of clinical practice guidelines.
2009 Spring
Adverse drug effects in hospitalized elderly: data from the healthcare cost and utilization project.
2010
Legal remedies for medical ghostwriting: imposing fraud liability on guest authors of ghostwritten articles.
2010 Aug
The chemical basis of pharmacology.
2010 Dec 7
Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine.
2010 Jan
Could chiropractors screen for adverse drug events in the community? Survey of US chiropractors.
2010 Nov 17
Screening of a chemical library reveals novel PXR-activating pharmacologic compounds.
2015 Jan 5
Patents

Sample Use Guides

50-100 mg 2-3-4 times per day. Course of treatment - 3-4 weeks.
Route of Administration: Oral
Adiphenine decreased the frequency of ACh-induced single-channel currents. Adiphenine decreased cluster duration (36-fold at 100 uM x L(-1)). Preincubation with adiphenine did not change amplitude but increased the decay rate (IC(50)= 15 uM x L(-1)).
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:55:52 GMT 2023
Edited
by admin
on Sat Dec 16 16:55:52 GMT 2023
Record UNII
YKG6OR043Q
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ADIPHENINE
HSDB   INN   MART.   MI   WHO-DD  
INN  
Official Name English
2-(DIETHYLAMINO)ETHYL DIPHENYLACETATE
Systematic Name English
ADIPHENINE [MART.]
Common Name English
BENZENEACETIC ACID, .ALPHA.-PHENYL-2-(DIETHYLAMINO)ETHYL ESTER
Common Name English
ADIPHENINE [MI]
Common Name English
Adiphenine [WHO-DD]
Common Name English
ADIPHENINE [HSDB]
Common Name English
adiphenine [INN]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29698
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
Code System Code Type Description
MERCK INDEX
m1419
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY Merck Index
FDA UNII
YKG6OR043Q
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
HSDB
3282
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
RXCUI
333
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY RxNorm
PUBCHEM
2031
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
SMS_ID
100000087702
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
WIKIPEDIA
Adiphenine
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID0022561
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
NCI_THESAURUS
C76456
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
MESH
C084829
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
ECHA (EC/EINECS)
200-599-0
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL353846
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
DRUG CENTRAL
94
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
EVMPD
SUB05272MIG
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
INN
2715
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
CAS
64-95-9
Created by admin on Sat Dec 16 16:55:53 GMT 2023 , Edited by admin on Sat Dec 16 16:55:53 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY